ClinicalTrials.gg
CompletedNCT00849030Updated Jun 6, 2012

ATAC - Arimidex, Tamoxifen Alone or in Combination

A Phase 3 interventional study of Anastozole (Arimidex) and Tamoxifen (Nolvadex) in Breast Cancer, sponsored by AstraZeneca. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9,358
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies testing anastrozole in Breast Neoplasms — 17 open to participants now, 28 under way, 10 of them phase 3. Anastrozole · Breast Neoplasms.

Enrollment
Largest of 109
9,358 · median 148
Started
1996
with 3 others
Phase 3
38 of 111
5 open now
Registered
41st of 111
by date
Lead sponsor
16 of 111
AstraZeneca

Among the 111 studies testing anastrozole in Breast Neoplasms, this one has the largest enrollment of the 109 interventional ones that give a count, is one of 4 that started in 1996, is one of 38 in phase 3, and was the 41st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 111 studies testing anastrozole in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About anastrozole

Anastrozole: first FDA approval 1995 (ARIMIDEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 45 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing anastrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven operable invasive breast cancer
  • Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal therapy
  • Women defined as

Exclusion criteria

Exclusion Criteria:

  • Patients in whom there is any clinical evidence of disease
  • Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements
  • Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9,358 participants (actual)

Study arms

  • Active comparator
    1

    Arimidex 1mg + Nolvadex placebo

    Drug: Anastozole (Arimidex) · Drug: Tamoxifen (Nolvadex) placebo

  • Active comparator
    2

    Arimidex placebo + Nolvadex 20mg

    Drug: Tamoxifen (Nolvadex) · Drug: Anastozole (Arimidex) placebo

  • Active comparator
    3

    Arimidex 1mg + Nolvadex 20mg

    Drug: Anastozole (Arimidex) · Drug: Tamoxifen (Nolvadex)

Interventions

  • 1mg, orally, once daily

    Also known as: Arimidex

  • 20mg, orally, once daily

    Also known as: Nolvadex

  • DrugAnastozole (Arimidex) placebo

    1mg, orally, once daily

  • DrugTamoxifen (Nolvadex) placebo

    20mg, orally, once daily

06

What researchers measure

Primary outcomes

  1. Time to recurrence of breast cancer

    Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death

  2. Safety and side effects

    Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death

Secondary outcomes

  1. Time to distant recurrence

    Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death

  2. Survival

    Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death

  3. New breast primaries

    Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1996, a primary completion of Jun 2001 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2009
First posted
Feb 23, 2009
Start
Jul 1996
Primary completionActual
Jun 2001
CompletionActual
Apr 2010
Last update
Jun 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00849030
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 23, 2009
Start date
Jul 1996
Primary completion
Jun 2001
Completion
Apr 2010
Last update
Jun 6, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Tamoxifen

Start the discussion